Navigation Links
Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
Date:12/21/2011

GREENWOOD VILLAGE, Colo., Dec. 21, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE)("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it has entered into definitive agreements with accredited investors to sell an aggregate approximately 2,220,255 of shares of its common stock, par value $0.0001 per share (the "Shares"), at a price per share of $4.25 in a registered direct offering for gross proceeds of approximately $9.436 million, before deducting placement agents' fees and estimated offering expenses.

The Shares are being offered directly by Ampio pursuant to an effective shelf registration statement previously filed with, and declared effective by the Securities and Exchange Commission on October 28, 2011. The Company anticipates that the net proceeds from the offering will be used for general corporate purposes and working capital. The closing of this offering is expected to occur on or about December 27, 2011, subject to the satisfaction of customary closing conditions.

Fordham Financial Management, Inc. and Summer Street Research Partners served as co- lead placement agents and Emerging Growth Equities, Ltd. served as the co-placement agent for the offering. When available, copies of the preliminary prospectus supplement, the prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission website at http://www.sec.gov or Fordham Financial Management, Inc., 14 Wall Street, New York, New York 10005.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any state or jurisdiction.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs").  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include, but are not limited to, statements relating to Ampio's ability to successfully complete the proposed offering and the use of proceeds therefrom, as well as other risks that are described in further detail in the preliminary prospectus supplement relating to the offering and in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact:
Investor Relations, Ampio Pharmaceuticals, Inc.   720-437-6500

 

 

 


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Responds to Recent Publications by Anonymous Short Sellers
2. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
3. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
4. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
5. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
6. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
7. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
8. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
9. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
10. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The Georgia State University College of Law new ... Urban Design Commission. , The annual award recognizes projects, programs, individuals and organizations that ... preservation of its physical heritage and the balance between the old and the new. ...
(Date:5/25/2016)... ... 2016 , ... A new update to Xsens popular data analysis ... a common Wi-Fi network and a mobile device. When paired with Xsens MVN or ... and use a mobile device to control the recording. , “The update adds ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... One Florida-based ... potential patients, according to an article published May 13th on Vanity Fair. ... comfortable with having snippets of their procedures broadcast to more than 800,000 Snapchat fans. ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Bank of America Charitable Foundation has awarded ... provide veterans a pathway to employment and successful careers in healthcare. On Wednesday, May ... Hallack, President and CEO of Medisend, parent organization and home of the General Myers ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies ... of injured workers across 15 states. The outcomes examined in these studies include ... medical care, and satisfaction with medical care. , “The goal of the studies ...
Breaking Medicine News(10 mins):